US Stem Cell Inc (USRM)

[TheHungryHippo]

BULLISH CEO DEFENDS OUR COMPANY:

In a written statement issued Thursday, MIAMI HERALD

Mike Tomás, CEO of U.S. Stem Cell,

a publicly traded biotech company, called the NEJM article “old news” and suggested it had been published to challenge the company’s most recent financial report that revenue had risen by 38 percent, from $2.2 million in 2015 to $3.03 million in 2016.

Tomás, who is a judge for the Miami Herald’s annual Business Plan Challenge, also pushed back on suggestions that the clinic’s stem cell treatments are unsafe.

“For nearly 20 years our clinics have conducted more than 7,000 stem cell procedures with less than 0.01 percent adverse reactions reported,” he said in the written statement. Tomás declined to comment on the patients, citing federal privacy rules. But he added that the clinic no longer offers eye treatments.